Portola pharmaceuticals, inc. (PTLA)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

-283,551

-292,876

-285,086

-306,636

-344,130

-350,544

-353,159

-364,923

-328,366

-285,620

-248,883

-256,978

-244,903

-268,113

-279,455

-243,576

-244,566

-226,505

-199,655

-180,291

-153,312

-137,125

-122,931

-105,687

-95,936

-83,352

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,846

3,000

3,136

3,133

3,138

3,102

3,046

2,934

2,662

2,410

2,168

2,000

1,971

1,924

1,792

1,608

1,379

1,311

1,342

1,429

1,573

1,542

1,486

1,422

1,381

1,359

0

0

0

Operating Lease, Cost

3,936

3,224

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount on investment securities

1,102

1,225

1,291

1,454

1,635

1,864

1,971

1,529

887

235

-368

-2,122

-1,748

-1,113

-6,684

-4,218

-3,632

-3,174

3,582

3,658

3,691

3,703

3,479

3,363

2,832

2,333

0

0

0

Non-cash interest expense

23,956

25,371

27,314

27,074

22,640

18,740

16,001

13,193

12,545

11,603

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense, net of capitalized labor

43,661

52,075

60,966

61,313

62,274

55,360

46,466

45,187

45,230

43,284

40,303

37,962

32,327

30,362

29,290

27,618

24,755

22,858

18,489

14,538

12,203

9,333

8,393

7,777

6,563

4,974

0

0

0

Embedded Derivative, Gain (Loss) on Embedded Derivative, Net

-710

2,931

6,136

7,690

5,195

6,357

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Provision for excess and obsolete inventories

2,317

4,152

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency remeasurement loss

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revaluation of convertible preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-24

0

0

0

Unrealized loss on foreign currency forward contracts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

Changes in operating assets and liabilities:
Inventories

75,929

58,830

-5,297

3,765

8,965

12,612

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Trade and other receivables, net

-4,377

7,698

11,086

10,534

10,094

-607

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unbilled - collaboration and license revenue

-2,909

-6,097

-6,084

-1,696

1,657

3,186

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Receivables from collaborations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

943

-73

-182

-152

-252

-154

-3,312

-794

-353

0

0

0

Prepaid research and development

-

-

-

-

-

-

-

-

-

-

0

0

-4,956

-

-3,864

9,607

2,092

15,290

0

0

0

-

-

-

-

-

-

-

-

Prepaid and other current assets

502

-3,812

2,587

-13,740

-5,734

7,496

-3,069

15,214

10,377

-235

-5,505

-8,776

-9,659

-10,055

3,536

2,168

33

-1,001

-2,414

-858

-833

1,383

0

0

0

-

-

-

-

Prepaid and other long-term assets

-10,459

3,813

14,807

17,666

26,807

10,968

-5,475

-6,263

644

4,395

3,293

-9,741

-7,009

-6,779

-6,671

2,108

-3,501

-3,619

2,980

13,904

14,644

15,559

0

0

0

-

-

0

0

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Accounts payable

2,422

-2,652

-5,835

1,567

-14,077

1,881

-3,919

-5,470

11,350

-5,242

9,020

6,986

-4,159

4,308

-15

-8,163

8,110

-4,061

-3,923

6,721

-2,179

10,763

10,904

1,092

274

-1,773

0

0

0

Accrued compensation and employee benefits

-

-

-

-

-

-

-

-

-

-

5,393

925

690

-653

-271

1,768

1,058

2,054

1,316

676

21

893

607

516

559

650

0

0

0

Accrued research and development

-1,146

-582

-1,046

-20,616

-3,729

-25,142

-7,469

16,965

10,936

21,155

8,711

1,543

-6,405

-377

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued and other liabilities

4,200

17,668

4,913

8,957

11,063

3,514

8,210

6,624

2,665

8,576

1,438

-327

558

-892

-994

1,500

-8,752

1,531

2,625

-974

12,965

-261

-11,448

-7,466

-5,519

-834

0

0

0

Deferred revenue

-1,154

-360

-1,983

-4,440

-2,635

-1,288

-3,233

-4,382

-9,018

-15,796

-10,685

-12,179

-4,373

18,747

14,274

17,186

10,781

-9,569

-9,567

8,416

14,888

31,374

31,731

16,392

13,405

1,169

0

0

0

Notes payable and long term royalty-based debt

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

-

-

-

-

-

-965

-928

-909

-890

-865

-861

-830

-808

-769

194

377

1,022

2,281

1,062

977

450

-42

195

69

-68

-878

0

0

0

Net cash used in operating activities

-245,388

-237,923

-227,966

-263,449

-301,273

-326,058

-328,389

-304,901

-262,009

-225,125

-172,794

-191,782

-209,655

-196,455

-240,259

-216,543

-198,443

-207,252

-194,126

-163,389

-134,614

-100,706

-77,356

-67,520

-64,692

-63,615

0

0

0

Investing activities
Capital expenditures, net

2,180

1,544

2,067

2,087

2,374

2,559

1,271

2,195

1,635

1,236

1,842

365

642

1,864

3,160

3,994

5,018

4,746

3,450

3,221

2,297

1,629

1,680

1,563

1,035

933

0

0

0

Decrease (increase) in restricted cash (SRX Cardio)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of investments

373,512

368,747

255,287

168,917

222,743

259,083

419,978

556,161

505,891

575,624

428,649

283,294

347,560

252,323

276,552

253,852

227,672

266,068

363,328

356,330

346,556

332,171

223,029

264,666

284,501

219,813

0

0

0

Proceeds from sales of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,365

8,509

8,009

0

0

0

Proceeds from maturities of investments

273,514

297,289

318,634

366,106

411,720

435,723

441,115

419,334

405,925

353,088

350,404

350,881

374,350

394,730

377,297

376,379

338,345

324,100

287,806

243,128

262,339

192,045

169,451

149,081

97,137

92,001

0

0

0

Net cash provided by investing activities

-102,178

-73,002

61,280

195,102

186,603

174,081

19,866

-139,022

-106,601

-228,772

-83,498

62,026

26,069

140,543

95,644

118,377

105,393

52,945

-76,358

-116,809

-86,911

-139,152

-53,893

-110,783

-179,890

-120,736

0

0

0

Proceeds from debt issuance, net

62,500

121,703

0

0

0

-

-

-

-

47,444

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock from public offering, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Debt issuance costs paid

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock pursuant to equity award plans

14,638

24,896

23,836

23,770

20,348

15,389

16,714

18,241

21,473

19,642

17,331

10,092

4,378

1,441

2,877

5,925

8,589

11,948

11,788

9,006

7,977

4,978

0

0

0

-

-

-

-

Payments of long-term obligation to collaborator

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-

-

-

-

-

-140

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from public offering of common stock, net of underwriters discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Payment of public offering cost

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

319,825

389,564

327,104

82,973

174,530

110,249

111,304

492,996

401,228

446,980

501,481

114,077

108,384

57,741

165,555

168,603

170,909

283,282

295,062

292,041

291,370

179,599

125,683

123,125

249,617

248,511

0

0

0

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-25

-2

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash

-27,766

78,637

160,494

14,583

59,860

-41,728

-197,219

49,073

32,618

-6,917

245,189

-15,679

-75,202

1,829

20,939

70,436

77,858

128,974

24,578

11,843

69,845

-60,259

-5,566

-55,178

5,035

64,160

0

0

0